Coherus BioSciences' (CHRS) CEO Dennis Lanfear on Q2 2018 Results - Earnings Call Transcript [Seeking Alpha]
Coherus BioSciences, Inc. (CHRS)
Last coherus biosciences, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.coherus.com
Company Research
Source: Seeking Alpha
Coherus BioSciences (NASDAQ: CHRS ) Q2 2018 Results Earnings Conference Call August 8, 2018 4:30 PM ET Executives Jean Viret - CFO Denny Lanfear - President, CEO and Chairman Vince Anicetti - COO Jim Hassard - SVP, Marketing and Market Access Matt Hooper - EVP and General Counsel Barbara Finck - CMO Analysts Mohit Bansal - Citigroup Jason Kolbert - H.C. Wainwright Douglas Tsao - Barclays Operator Ladies and gentlemen, thank you for standing by, and welcome to the Coherus BioSciences Second Quarter Earnings Conference Call. My name is Sonya, and I will be your conference operator for the call today. At this time, all participants are in a listen-only mode. And as a reminder, this conference call is being recorded. I would now like to turn the call over to Jean Viret, Chief Financial Officer. Please go ahead. Jean Viret Thank you, Sonya and good afternoon, everyone. After close of market today, we issued a second quarter financial results press
Show less
Read more
Impact Snapshot
Event Time:
CHRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CHRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CHRS alerts
High impacting Coherus BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
CHRS
News
- Coherus Biosciences: Dumping One Drug But Showing Promise With Another [Seeking Alpha]Seeking Alpha
- Coherus BioSciences, Inc. (NASDAQ: CHRS) had its price target lowered by analysts at HC Wainwright from $13.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Coherus BioSciences, Inc. (NASDAQ: CHRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.MarketBeat
- Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Global Neutropenia Market Competitive Analysis and Forecast Report to 2028, Featuring BeyondSpring Pharmaceuticals, Coherus Biosciences, Myelo Therapeutics and Spectrum Pharmaceuticals [Yahoo! Finance]Yahoo! Finance
CHRS
Earnings
- 3/13/24 - Miss
CHRS
Sec Filings
- 3/28/24 - Form S-8
- 3/15/24 - Form 10-K
- 3/13/24 - Form 8-K
- CHRS's page on the SEC website